Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02741102

Uterine Transplant in Absolute Uterine Infertility (AUIF)

This study will examine the feasibility of initiating a uterine transplant program for Absolute Uterine Factor Infertility (AUFI) at Brigham and Women's Hospital. The investigators plan to screen 30 patients with a goal of enrolling 10 patients. (5 donors and 5 recipients) After careful screening, appropriate candidates will undergo IVF, Uterine Transplantation, Embryo Transfer, Pregnancy and Delivery. Once the uterus is explanted, five years of follow-up is planned.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Location status: Recruiting

Location contact

Stefan Tullius, MD

CONTACT

About this study

There are approximately 9.5 million women in the United States with Absolute Uterine Factor Infertility (AUFI).Congenital uterine infertility in women is linked to a malformed or absent mullerian system termed MRKH - Rokitansky's or Mayer-Rokitansky-Kuster-Hauser Syndrome). Additional causes of acquired uterine infertility include a hysterectomy subsequent to life-threatening hemorrhage during childbirth or as a consequence to a hysterectomy related to cervical cancer or for large symptomatic fibroids. Additional causes may include intrauterine adhesions subsequent to surgical abortion or infection.

Uterine transplantation will provide a much needed medical option for many women in the U.S. and overseas who are unable to carry their own children based on uterine infertility. Centers outside of the US have initiated uterus transplant programs. Initial attempts were reported from Saudi Arabia. While the deceased donor transplant had been successful, successful pregnancies were not achieved. Another deceased donor transplant had been performed in Turkey with a uterus procured from a deceased donor. Although several IVF attempts had been performed, they had not resulted in live births.

Uterus transplants from live donors have been successful. In October 2014, Swedish doctors treating a woman born without a uterus, announced the world's first live birth of a healthy baby boy after a live donor uterine transplantation. Since then, an additional three babies have been born in Sweden to mothers who received live donor uterus transplants. A fifth baby is at term and a 6th pregnancy has been reported.

For this study, the investigators plan to screen 30 patients in order to enroll 10 patients, 5 recipients and their respective donors. Prospective recipients will undergo comprehensive medical and psychological evaluation. If deemed an appropriate candidate, In Vitro Fertilization would be started with the goal of obtaining 6 normal embryos for implantation. The uterus of a suitable live donor would then transplanted into the recipient. The recipient would need to take potent anti-rejection drugs and undergo regular assessments for rejection. After one year, embryo transfer to the transplanted uterus would be tried. Up to 6 cycles would be attempted hopefully resulting in pregnancy. If pregnancy results, the recipient would be followed by the high risk pregnancy team. Delivery will be by Caesarian Section. A woman may have up to 2 pregnancies with the transplanted uterus. The uterus is later removed so the recipient no longer has to take anti-rejection drugs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Uterine Transplant Inclusion/Exclusion Criteria

RECIPIENT:Inclusion Criteria

  • Age 18-40
  • Clinical evidence of AUFI (Absolute Uterine Factor Infertility)
  • Able to produce at least 6 normal embryos by IVF for future use
  • Reasonable weight with BMI (Body Mass Index) less than 30.
  • Normal kidney function
  • Able to undergo transplant and be compliant with treatment
  • Has stable partner and social supports
  • Partner willing to undergo psychological evaluation and receive immunizations as recommended
  • Stable home environment to support a child

Exclusion criteria

  • Active smoking, alcohol use or use of illicit drugs
  • Inability to comply with required treatment (taking pills, having biopsies, frequent appointments )
  • Having a condition that would make pregnancy or taking anti rejection medicines too risky.
  • Active infection: Human Immunodeficiency Virus (HIV) , Tuberculosis, Hepatitis B, Hepatitis C
  • History of extensive abdominal or pelvic surgery
  • History of abnormal Papanicolaou test (PAP smear) or genital warts
  • History of pelvic inflammatory disease

DONOR:Inclusion criteria

  • Age over 40 up to age 60
  • Has completed having a family
  • Previous pregnancies were carried to term (no miscarriages)
  • Able to take a birth control pill containing estrogen
  • Weight reasonable with BMI (Body Mass Index) of 30 or less
  • Good social supports

Exclusion criteria

  • Active smoking, alcohol use or use of illicit drugs
  • Psychiatric illness
  • Cervical or endometrial polyps (growths) or tumors in the uterus muscle
  • History of more than 1 Caesarean section
  • History of abnormal PAP smear or genital warts
  • Internal scarring from extensive abdominal or pelvic surgery
  • Hypertension, Coronary artery disease, Chronic Obstructive Lung disease (emphysema) and Diabetes
  • Active cancer or incompletely treated cancer
  • Active infection including Human Immunodeficiency Disease (HIV) , Tuberculosis, Hepatitis B or Hepatitis C
  • Significant history of either blood clots or bleeding tendencies
  • Evidence of coercion or exchange of money or goods for donating the organ

Treatment and study plan

Uterine Transplant

Procedure

Treating Absolute Uterine Factor Infertility by Uterus Transplant. Potential recipients undergo IVF to obtain 6 embryos for cryopreservation followed by live donor uterine transplant. After 1 year, embryo transfer is done to achieve pregnancy. Delivery is by Caesarian section. The recipient may have up to 2 children by these methods and then the uterus is removed so that immunosuppression can be stopped.

Primary outcomes

  1. Number of successful live births following uterus transplant/embryo transfer

    Time frame: 2 years after uterine transplant

    Full term live birth by caesarian section after uterus transplant and IVF

Secondary outcomes

  1. Rate of complications during pregnancy in uterus transplant recipient

    Time frame: 9 months after pregnancy achieved by embryo transfer

    Close monitoring for pre-eclampsia, hypertension, diabetes, and pre-term delivery. Monitoring for signs of rejection, should it occur, you would first be treated with steroids

  2. Rate of complications following uterine donation

    Time frame: Up to 2 years post donation

    Monitoring for excessive bleeding, infection and bladder dysfunction. Also monitoring blood clots in the legs.

  3. Impact of uterine donation on donor quality of life

    Time frame: Up to 2 years post donation

    Measured by serial SF 36 QOL survey by psychiatrist at pre-donation and at follow-up appointments. The SF-36 evaluates general health perception, perceived change in health over time, physical functioning, role limitations due to physical or emotional health, and activity limitations. Emotional well-being will also be assessed using the Hospital Anxiety and Depression Scale (HADS), a validated questionnaire scored from 0 to 3 per item.

  4. Cost comparison for uterine transplant vs. surrogacy vs adoption

    Time frame: Up to 5 years after uterine transplant

    At the end of the study, investigators will calculate average cost of each modality, i.e. transplant vs surrogacy vs adoption to compare the three alternatives to infertility

  5. Impact of uterine transplant on quality of life

    Time frame: Up to 5 years after uterine transplant

    Measured by serial SF 36 QOL survey by psychiatrist pre-transplant and at follow-up appointments..

Study contacts

Contact information is provided by the study sponsor or research team.

Stefan G Tullius, M.D.

CONTACT

[email protected]

617-732-6866

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Apr 18, 2016
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.